CSTL — Castle Biosciences Share News
0.000.00%
Last trade - 00:00- $1.03bn
- $776.11m
- $344.23m
Brief: BTIG Raises Castle Biosciences Target Price To $32 From $30
Castle Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Castle Biosciences Q2 Basic EPS USD -0.7
Castle Biosciences Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Study Data From Castle Biosciences' Collaboration With The National Cancer Institute's SEER Program Registries Published In JCO Precision Oncology
Brief: Castle Biosciences said Decisiondx-SCC Test Was Able To Stratify 3-Year Metastasis Free Survival Rates
U.S. RESEARCH ROUNDUP-Apple, Cabot, Epam Systems
Brief: Castle Biosciences' Idgenetix Show Significant Improvement In Medication Response In Patients With Major Depressive Disorder
U.S. RESEARCH ROUNDUP-Builders FirstSource, Weave Communications, Zoominfo Technologies
Brief: Castle Biosciences posts Q1 basic EPS USD -1.1
Castle Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Castle Biosciences Reports First Quarter 2023 Results
Castle Biosciences Inc expected to post a loss of 89 cents a share - Earnings Preview
Brief: Castle Biosciences Says Tissuecypher Test Results Can Increase The Likelihood Of Appropriate Management Decisions For Barrett's Esophagus Patients With Low-Grade Dysplasia
U.S. RESEARCH ROUNDUP-Axon Enterprise, Dorman Products, Verisk Analytics
Castle Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Castle Biosciences Reports Fourth Quarter And Full-Year 2022 Results
Castle Biosciences Inc expected to post a loss of 84 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Apollo Global Management, Microsoft, ServiceNow